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Abstract
Aims: The use of hypo fractionated irradiation of the whole breast has regained much interest after the
publication of the results of large randomized trials showing equivalent results as using standard fractionation
(START A and B, randomized START pilot trials, Canadian trial). Due to the relatively low numbers of patients
treated with hypofractionation to the supraclavicular ±axillary (S/A) region, the question of the brachial plexus
tolerance continues to be discussed.
Aim of this work was to assess the high grade long term tolerance of the brachial plexus in our patients treated
with 13x 3.3Gy to the S/A lymph nodes, in order to contribute to the question of plexus tolerance.
Materials and Methods: Between 1967 and 1977, 130 female breast cancer patients underwent postoperative
hypo fractionated radiotherapy at the University Hospital Zurich. The most used schedule was 13x 3.3Gy midline
dose, 3x/week (n=124) to the S/A region applied by equally rated antero-posterior/postero-anterior portals. A first
assessment of the cohort was performed in 1994, which has been updated in December 2013. Patients with a follow
up period <5 years or loco-regional disease have been excluded in 1994 (n=4, all without plexopathy). Pre-radiation
surgery consisted of radical mastectomy in 98% and breast conserving operation in 2% of all patients, including
axillary dissection. Pathological stage was pT1/2/3/4 in 28/58/10/4%; with pN0/pN+ in 57/43%. The mean/median
follow up time of the cohort was 28.1/26.6 years (range, 7.2-44.8).
Results: One grade 2 brachial plexus neuropathy was observed.
Conclusion: The long term follow up in our patients corroborates the hypothesis of a total mid plane dose to the
S/A region between 40-42Gy in 13 fractions being comparably safe as 25x 2.0Gy to 50Gy.
Keywords: BPN; Brachial plexus tolerance; Hypo fractionation;
Radiation-induced brachial plexus neuropathy; Radiation tolerance
Introduction
The use of hypo fractionated irradiation of the whole breast has
regained much interest after the publication of the results of large
randomized trials showing equivalent results as when using standard
fractionation (START A and START B, Canadian trial, randomized
pilot trial for the START trial [1-6]. Based on these results from >7000
patients, the national institute for health and clinical excellence
(NICE) has included the hypo fractionated regime with 40Gy/3 weeks
in 15 fractions into its national guidelines [7], (http://
www.nice.org.uk).
Some centers use hypo fractionation since many years, resulting in
a large, albeit retrospective experience with these regimes [8-11].
History of the use of hypo fractionated radiation schedules for the
breast at our institution.
During the period between 1967 and 1977, two regimes were used
at our centre for curative irradiation of the whole breast or the chest
wall: 5x 2.0Gy per week to 50Gy (± boost to 60-66Gy), or -in most
cases- 3x3.3Gy per week to 42.9Gy. For logistic reasons, hypo
fractionation was preferred in nearly all ambulatory patients with
curative postoperative (post-mastectomy and breast conserving
surgery) irradiation for breast cancer. In that period, in most patients
the regional lymph nodes have also been included in the elective
treatment volume. Since the opening of our department decades ago,
life-long follow up of all patients used to be the standard practice;
therefore nearly all irradiated patients had regular physical check-ups
in our department, however since approximately 1985, most patients
were no longer followed by physical examination at our department
but regularly contacted by phone and/or by collecting follow up
information with help of questionnaires.
After the publication of the results of the large fractionation study
of the British Institute of Radiology (BIR) in 1978 [12] (showing
inferiority of hypo fractionation as compared to norm fractionation
schedules), hypo fractionation has, as a consequence, been abandoned
in the curative treatment setting at University Hospital Zurich (USZ).
In 1993, Olsen et al. reported a relatively high rate of lesions of the
brachial plexus after standard irradiation with 50Gy [13]. Motivated
by that publication, in 1994, we reviewed the medical charts of all our
loco-regionally controlled breast cancer patients treated with curative
postoperative hypo fractionated radiation between 1967 and 1977,
with focus on late term tolerance of the brachial plexus following
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3.3Gy per fraction to the axillary ± supraclavicular (A/S) lymph nodes.
Our first evaluation of the here presented cohort back in 1994
included a physical examination with focus on BPN in 25/130 patients,
with a mean follow up of 18 years (5-36) post radiation; 56 additional
patients could be contacted for a detailed phone call interview
specifically focusing signs and symptoms of substantial BPN. For the
remaining 49 patients (loss of follow up or death), specific information
was extracted by reviewing their records: in 89% of the cohort there
was no clinical sign of brachial plexus alteration. 13 women (10%)
treated with 13x 3.3Gy described subtle neurological symptoms like
pain in the arm and mild hypaesthesia (starting ∼1-17 years post
treatment, mean time to appearance not exactly known as symptoms
may have been mild and therefore not always recognized/indicated by
patients), which were not clinically relevant (grade 1 BPN, see grading
below); objectively, a mild subcutaneous induration of the irradiated
region was observed in those women. Of importance in this context is
the fact that most patients treated in that historic era had undergone
Halsted radical mastectomy and radical axillary lymphonodectomy.
Pleasingly, only one mild subjective and objectively not limiting
grade 2 brachial plexus neuropathy (BPN) in one of the clinically
assessed patient treated with 13x 3.3Gy was seen at that time.
Aim of this work
Due to the relatively low number of patients treated with hypo
fractionated radiotherapy to the S/A region [14-19], the question of
the brachial plexus tolerance continues to be discussed. In December
2013, we performed an update of the above described
hypofractionation cohort, at a mean/median follow up time of
meanwhile 28.1/26.6 years (7.2-44.8), aiming to re-assess the late term
tolerance of the brachial plexus.
Methods and Materials
Patients
In December 2013, an update of the above described cohort was
performed motivated by the again increasing interest in hypo
fractionated radiation schedules nowadays.
The medical records of the eligible 130 patients were still available
and were reviewed, in order to assess the long term tolerance of the
brachial plexus following our 1967 to 1977, predominantly used
hypofractionation schedule with 13x (12-15x) 3.3Gy in 3 fractions per
week to the breast and S/A lymph nodes, (Table 1).
Parameters Hypofractionation Cohort
number of patients 130
treatment interval 1967-1977
mean ageat radiation (range) 54 (27-77) years
at first analysis, 1994 73 (50-97) years
at last analysis, 2011 76 (50-98) years
T stage pT1/2/3/4 28/58/10/4%
N stagepN+/pN0 43/57%
follow up (FU) time
mean / median (range), in years:
all 28.1 / 26.6 (7.2-43.6)
lost of FU cohort (death, moved; 33%) 18.7 / 18.2 (7.2-27) *
known dead of disease (DOD, 2%) at 18.5 and 25.6 years
INED (33%) 30.8 / 29.5 (20-38.9)
ANED (63%) 27.1/23.7 (7.2-43.6)
ANED, still alive (06/2011, 15%) 39.6 / 40.6 (38.3-42.5)
6-10 years FU 7%
>10-20 years FU 28%
>20-30 years FU 59%
>30 years FU 6%
previous breast surgery
(mostly radical) mastectomy 98%
breast conserving 2%
hypofractionation schedules, 3f/w
[BEΔ2ΓΨ, α/β=2/α/β=3, 5φ/ω]  
13x 3.3Gy= 42.9Gy[56/54Gy] 124
12x 3.3Gy= 39.6Gy[52/50Gy] 2
15x 3.3Gy= 49.5Gy[66/62Gy] 2
14x 3.3Gy= 46.2Gy[61/58Gy] 1
14x 3.5Gy= 49.0Gy[68/64Gy] 1
allive with known disease
at first analysis, 1994 0, 1
at last analysis, 2011 2, 5
Table 1: Characteristics of the assessed hypofractionation cohort
(n=130).
* 3 patients were alive with disease when last time seen, all others
ANED; Loss of follow up was in most patients due to emigration to
other countries; ANED: Alive and No Evidence of Disease when last
time seen; AD: Alive with Disease when last time seen; DOD: Died of
Disease; INED: Inter-currently died, No Evidence of Disease
None of the historic patient cohort underwent chemotherapy, and
breast conserving surgery was performed in only 2%. In all patients the
A/S lymphatic pathway was included into the radiation volume.
Exclusion criteria as defined for the first assessment in 1994 were: (a)
follow up period information of <5 years, and/or (b) local or regional
recurrence. Four (4/134) loco-regionally disease free patients were
excluded due to a too short follow up time; all four patients had no
signs of BPN at last contact. From all of the remaining 130 patients any
follow up information (i.e. clinical examination at our institution
and/or information by phone, letters, charts) was available; in 78% of
the cohort regular physical examinations at our institution for >5 years
was performed. Since approximately 1985, most patients were no
longer regularly physically examined at our department, but were
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annually contacted by phone and/or questionnaires during the first 10
years and thereafter biannually. In addition, follow up information of
all patients used to be regularly collected based on follow up letters of,
or phone calls to caring family doctors and gynaecologists.
Methods
Definition of the used grading for PBN: In 1994, the following
grading system has been defined and was used since to assess BPN in
our patients:
Grade 0: no symptoms
Grade 1: anamnestic mild arm pain or weakness, without impact on
daily life, plus the following clinical symptoms: dysaesthesia, hypo-/
areflexia
Grade 2: paresis, functionally nonlimiting (plus all grade 1
symptoms)
Grade 3: disabling paresis or paralysis, with consecutive limitations
in daily life
Radiation techniques
The used hypofractionation schedules are shown in Table 1.
The estimated Biological Effective Dose (BED, = D (1+d/(α/β)) to
the used hypofactionated schedules for normofractionation (2Gy/day,
5 fractions (f)/week) is calculated for an alpha/beta ratio of 2Gy and
3Gy for the brachial plexus.
The A/S region radiation therapy has been performed by opposing
antero-posterior (ap-pa) fields with equal weight and a midline dose of
39-49Gy in 3 fractions/week. Matching between ap-pa A/S and oblique
opposed breast tangential fields was performed using tilt gantry and
table rotation to compensate for beam divergence of the cobalt 60
machine as used in that period. Calculation of midline dose was then
performed by manual calculation using depth dose tables. Source skin
distance was 55-90 cm (90 cm in most cases). An example of an old
simulation film (1972) of a supraclavicular/axillary radiation field is
shown in Figure 1.
Figure 1: Simulation film of a supraclavicular/axillary radiation
field (1972).
Two of the authors (KL and CG) performed recalculations of the
dose distribution in 3 patients by using a CT calculation program for
Cobalt 60. Recalculations were based on a model for a Siemens
‘Gammatron R’ cobalt unit (the machine that has been used for
treatment of this patient cohort; model provided by Dr Richard Lösch,
Klinikum St. Marien, Augsburg, Germany) in the Pinnacle [30]
version 8.0 treatment planning system (TPS, Philips Healthcare,
Andover MA).
Figure 2 shows dose distributions to the brachial plexus using
different set ups as resulting from these recalculations; Figure 3 shows
related dose volume histograms (DVHs) of the arm plexus using
different treatment set ups (a-d).
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Figure 2: Dose distribution. a) Sagittal view of the dose distribution of opposed 6MV fields (midline dose) with 100cm source –isocenter
distance b) Axial view of the dose distribution of opposed 6MV fields (mid plane dose) with 100cm source –isocenter distance.
Figure 3: Dose Volume Histograms (DVH) of the arm plexus for different treatment set up, a) 6MV ap beam, 13x3.2Gy (max of build-up), b)
6MV ap-pa opposed beams, midline dose, equally weighted 13x3.2Gy, c) Co60 ap-pa opposed beams, midline dose, equally weighted
13x3.168Gy, d) Co60 ap-pa opposed beams, midline dose, equally weighted 13x3.3Gy.
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Statistics
StatView® (Version 4.5) with its integrated calculation programwas
used as data base andfor related calculation of follow up (no further
statistics were calculated due to only one event).
Results
Follow up characteristics of the assessed cohort are listed in Table 2
and Figure 4.
Follow Up
(FU)
clinical FU at
USZ
FU information from letters/charts/
calls known death
years (y) % letters/charts/calls +/- clinical FU,% %
<5y 22 0 0
>/=5y 78 100 16%
5-10y 19 7 0
>10-15y 23 9 0
>15-20y 15 19 2
>20-25y 9 35 2
>25-30y 10 24 5
>30y 2 6 7
Table 2: Follow up characteristics of the own cohort.
Partial hypaesthesia of the upper arm was a frequently seen
symptom, but was also recorded in the charts of many patients who
had no S/A radiation, and may be related to the substantially more
radical operation techniques (Halsted) used in the past. A frequent
finding was a fat atrophy in the shoulder region. In addition, in one
patient a subtle weakness of the arm was described, which, however
was not limiting in the daily routine work (grade 1, diagnosed >16
years post treatment).
No grade 3BPN events developed in our cohort with a mean
observation time of 28 years.
Figure 4: Kaplan Meier follow up curves analysed according to patients followed by information from charts, letters, phone calls +/- clinical
FU at our department (1), isolated depicture of the clinical follow up at our department (2) and overall survival based on confirmed
informationaboutpatients’death.
The above mentioned patient with grade 2 BPN as stated in1994
(see ‘introduction’), was clinically examined for the last time in
11/2013,nearly 45 years after radiation therapy: this lady presents with
a still persisting grade 1-2 BPN, no pain, being a content and active
and indicating no additional complaints. Her history was the
following: in the age of 40 this patient underwent breast conserving
surgery for a T1N0 breast tumor in 1969, followed by hypo
fractionated radiation with 13x 3.3Gy to the residual breast and the
axillary region uses an ap-pa field technique, and to the
supraclavicular region using an anterior field (calculated to 3cm
depth). The arm plexus was most likely in the region of this field
overlap. In 1983, 14 years later, the patient experienced a local
recurrence of her disease and underwent a mastectomy and axillary
revision. Grade 2 PBN with some degree of paresis of the arm was
diagnosed in 1994. The patient kept on being able to work as a
secretary performing mostly typing duties. As this activity requires
substantial fine motor skills, the lesion was then classified asa grade 2
BPN.
Discussion
The aim of this work was to assess long term high grade BPN
following hypo fractionated radiation to the arm plexus.
No grade 3/4 PBN was observed in the assessed cohort of patients
treated with hypo fractionated radiation therapy using 3.3Gy in mostly
13 fractions.
The weakness of the study is its retrospective approach, and the lack
of a specific investigation questionnaire regarding the brachial plexus
function in order to detect milder BPN symptoms. More subtle
degrees of BPN may have been missed by this method, although
probably of limited relevance in daily life, and difficult to clinically
differentiate from possible long term sequels after radical mastectomy,
as performed in most patients of this historic cohort. Of importance to
note in this context is that neuropathic shoulder arm symptoms
and/or signs are common following mastectomy (±chemotherapy)
only: in a prospective study on 100 surgery-only patients (50 patients
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with modified radical mastectomy, 50 patients with wide local excision
and axillary clearance treated between 2004-2006), 60% of patients
reported one or more symptoms: numbness and pain in 39% each
[20]. Arm symptoms were also reported most commonly during the
first year after surgery ±radiotherapy to the breast by Liljegren et al in
their randomized trial on 381 patients, and a further reduction was
noted over the subsequent years by around 40-50% [21]. In the
randomized ALMANAC trial >28% of 405 patients reported at least
one arm symptom by 18 months post axillary surgery [22]. Engel et al.
assessed 5-year quality of life data of 1131 patients in a prospective
cohort study and found new and remained arm problems in 6% and
34% at year 4-5, respectively [23].
In the large Manchester analysis of >2000 cases treated with 40Gy/
15fractions in 3 weeks, the same methodology was used to assess the
follow up information (review of the case notes of all patients/
contacting GPs and/or surgeons for information on patients who had
been lost to follow-up or discharged) [24].
The focus of our analysis was on clinically relevant BPN (grade ≥ 2),
which is hardly to miss by patients and caring physicians. Grade >/=2
symptoms are expected to be spontaneously reported by patients and
related symptoms are evident at regular physical check-up, thus the
presented study results are considered reliable.
The strength of the analysis lays in its long follow up time period of
a relatively large sample size of patients treated with a homogeneous
radiation regimen applied during one decade in a single institution, as
well as in the regular clinical long term follow up at the same
department (Table 1).
Regarding the BPN scoring, there is, to our knowledge, no specific
standard available. Olsen et al. [13] defined a three-step grading, with
‘disabling BPN in daily life’ as grade 1: presence of disabling sensory
disturbances, weakness, atrophy or hypoactivity of muscle stretch
reflexes), ‘mild BPN’ as grade 2: all of grade 1, but mild), and grade 3:
no BPN (absence of neurological signs and symptoms). Bajrovic et al.
graded BPN using a modified LENT-SOMA four-step score [24], while
we grouped symptoms to a three-step scale with emphasis on the
functional aspect (see ‘methods’); our grade 3 compares to the grades 3
and 4 in Bajrovic et al. and Olsen et al. grade 1, respectively.
A few papers describe rare instances of plexus lesions after a dose of
50Gy with 2Gy/fraction or 45Gy with 2.25Gy/fraction. Listed in Table
3 are selected published data on the rate of brachial plexus neuropathy
(BPN) following differently fractionated radiation therapy of the
breast and axillary ± supraclavicular regionpublished in the literature
[1-3,9,13,14,25-33], showing a low rate of high grade BPN, comparable
as following normal-fractionation.
FRACTIONATION Author[ref] Year
Treatment
Interval
Follow up
years
(range) n pat
Dose/Session
(Gy)
Total
Dose
(GY)
~BED2Gy α/
β=2Gy/3Gy % BPN [grade]
Interval to
BPN mean
(range)
 [33] 1996 1958-1962
na (na -
2.5) 33 4.58 55 90/83
73% [1-3] 0.5-2.5 y
     84 4.25 51 80/74 15% [1-3] 0.5-2 y
 [14] 1987 1980-1983 na (na - 7) 250 3.4 51 69/66 2.4% [1 and 3] 0.3-2 y
H [31] 1990 1982-1984 na (3-5.5) 338 3 45 56/54 5.90% (1-4 year)
 [9] 1995 1981-NA
median 8
(2-11) 113 2.67 40 47/46
0% 0
 [26] 1995 1981-NA
median 8
(1-11) 334 2.67 40 47/46
0%
0
Y [32] 1997 1979-1986
median
12.5 (na) 164 2.19 35 37/36
0%
0
 [29] 2000 1963-1965 (na - 34) 71 4 44 66/62
63% [1-4] 4.2y (<1-19
y
 
[24]
2000 1989-1992
alive:
median
5.9 (na -
10) 1148 2.66 40 47/46
0%
0
P [27]* 2002 1984-1999 (na - 10) 89 6 30 60/55 0% [2-4] 0
 
[25]
2004 1980-1993
median
7.3
(2.5-18) 332 2.6 52 60/58
14% [1-4] >/=G3:
0.8%/ y
 
[1]
2008 1999-2002
median
5.1 (max.
8.0) 119 3.2 42 54/52
0.1%[1]
2y
O [2] 2008 1999-2001
median 6
(max. 8.0) 74 2.67 40 47/46
0
0
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[3]
2013 1999-2002
median
9.3 (max.
12.4) 193 3.20 or 2.67 41.6/40
54/52;47/46 none
mentioned
0
 
own study
2014 1967-1977
median
26.6
(7-45.2) 124 3.3 43 56/54
1%[2]
25y
 [30] 1992 19968-1985
median
6.6
(<1-19) 1117 2 50 50
1.8% [1-2] 10 months
(1.5-77)
N [13] 1993 1982-1990 median 4 128 2  50 9%/5% [1/3 no latency
O [31] 1990 1982-1984 (3-5.5) 111 1.8 54 51 1% [?] (1-4 years)
R [28] 1990 1977-1985 median 10 697 2 50 50 <1% [na] na
M
[1]
2008 1999-2002
median
5.1 (max.
8.0) 309 2 50 50
0%
0
O [2] 2008 1999-2001
median 6
(max. 8.0) 153 2 50 50
0%
0
 
[3]
2013 1999-2002
median
9.3 (max.
12.4) 462 2 50 50
none
mentioned
0
Table 3: Selected published data on the rate of brachial plexus neuropathy (BPN) following differently fractionated radiation therapy of the breast
and axillary ±supraclavicular region.
*: postoperative axillary radiation after axillary melanoma
metastasis dissection, 2 fractions/week.
START A/B: no information available regarding axillary vs.
supraclavicular vs. axillary and supraclavicular treatment volumes.
According to an analysis included in the protocol of the START A
trial, at least in some of those patients the dose per fraction, the total
dose and the dose to the plexus were higher than the prescription dose.
This was also the case in our patient who developed grade 2 PBN (see
‘method’). With the same relevance is the published decade long
experience of supraclavicular and axillary irradiation with 40Gy in 15
fractions [24].
For our historic group radiated with 3.3Gy to the midline dose in 13
fractions, we re-calculated the dose distribution based on the planning
CT of actual patients treated for breast cancer (Figures 2 and 3), the
range of DVHs in this historic cobalt group includes very well the
DVH of an equally weighted photon 6MV opposed field applying the
dose of 13 fractions with 3.2Gy used in one of the arms of the START
A trial.
Considering published results on the incidence and risk of various
radiation regimes for brachial plexus lesions–including own results-,
we come to the following conclusions:
The results from our historic group corroborate that a hypo
fractionated regime as used in the START A and B trials as well as in
the related pilot trials, and not exceeding the dose limits as listed in the
START protocol (START A Trial Final Protocol; Standardisation of
Breast Radiotherapy, July 1998 [13,30]), is as safe as applying 25
fractions with 2.0Gy target dose.
The results from our historic group corroborate the results in the
START protocol (START A Trial Final Protocol; Standardisation of
Breast Radiotherapy, July 1998): ‘It seems reasonable to assume that an
absorbed dose equivalent to 50Gy in 2Gy fractions at the level of the
brachial plexus is safe in the absence of axillary surgery or
chemotherapy. ‘Safe’ means a risk of radiation-induced BPN much
lower (<1%) than the risk of malignant BPN were no radiotherapy to
be given’.
The results of the Christie Hospital in Manchester based on >2000
patients [24] treated with a regime of between 40 and 42Gy in 15 or 16
fractions also supports this conclusion.
Conclusion
The long term follow up in our patients corroborates the hypothesis
of a total mid plane dose in the supraclavicular/axillary region between
40-42Gy in 13 fractions being comparably safe as the normo
fractionated regimen using 25x 2.0Gy to 50Gy.
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